cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14554188.v1
title: Supplementary Material for: Plasma Amino Acids and Risk of Impaired Lower-Extremity Function and Role of Dietary Intake: A Nested Case-Control Study in Older Adults

description: <b><i>Introduction:</i></b> Amino acids are key elements in the regulation of the aging process which entails a progressive loss of muscle mass. The health effects of plasma amino acids can be influenced by dietary intake. This study assessed the prospective association between amino acid species and impaired lower-extremity function (ILEF) in older adults, exploring the role of diet on this association. <b><i>Methods:</i></b> This is a case-control design comprising 43 incident cases of ILEF and 85 age- and sex-matched controls. Plasma concentrations of 20 amino acid species were measured at baseline using liquid chromatography-tandem mass spectrometry, and incident cases of ILEF were measured after 2 years by means of the Short Physical Performance Battery. Conditional logistic regression models were used to assess longitudinal relationships. <b><i>Results:</i></b> After adjusting for potential confounders, higher levels of tryptophan were associated with a decreased 2-year risk of ILEF (OR per 1-SD increase = 0.64, 95% CI = [0.42, 0.97]), while glutamine and total essential amino acids were linked to higher ILEF risk (OR = 1.57, 95% CI = [1.01, 2.45]; OR = 1.89, 95% CI = [1.18, 3.03], respectively). Those with a lower adherence to a Mediterranean diet, a higher BMI, a higher consumption of red meat, and a lower consumption of nuts and legumes had an increased risk of ILEF associated with higher levels of essential amino acids. <b><i>Discussion/Conclusion:</i></b> Some amino acid species could serve as risk markers for physical function decline in older adults, and healthy diet might attenuate the excess risk of ILEF linked to essential amino acids.
DOI: 10.6084/m9.figshare.14554173
title: Supplementary Material for: Chronological Skin Changes Through Postmastectomy Radiotherapy Based on Radiotherapy Techniques: Using Quantitative Dermatological Measurements

description: <b><i>Background:</i></b> There has been few research on how to measure skin status quantitatively throughout the course of radiotherapy (RT). We evaluated the changes in the skin induced by 2 different RT techniques using objective measurements in breast cancer patients. <b><i>Methods:</i></b> In this prospective study, between August 2015 and March 2019, serial measurements of the dermatological factors during and after postmastectomy radiotherapy (PMRT) were made in 40 breast cancer patients. PMRT was performed using the conventional photon tangential technique (PTT) or patient-tailored bolus technique (PTB). We analyzed these measurements using a mixed effect model and compared the clinically evaluated radiation dermatitis and patient-reported outcomes (PROs). <b><i>Results:</i></b> The trend of changes in melanin and erythema was significantly different between the PTB and PTT groups (<i>p</i> = 0.045 and 0.016, respectively). At the 3-month follow-up erythema intensity and melanin were higher in the PTB group than in PTT group (both <i>p</i> &lt; 0.001). Eight patients (40% in the PTB group) reported grade 2 radiation dermatitis and 1 patient (5% in the PTB group) reported grade 3 radiation dermatitis. No grade 2 or higher radiation dermatitis was found in the PTT group. Ten patients (50%) in the PTB group and 3 patients (15%) in the PTT group reported severe erythema likely due to questionable clinical evaluation, but hyperpigmentation was rarely reported at the follow-up visits. <b><i>Conclusion:</i></b> The PTB group showed higher intensity of erythema at the end of RT than the PTT group and the increase in melanin lasted until the 3-month follow-up visits in the PTB group. Moreover, patients subjectively appealed more severe symptoms following PTB in PROs.
DOI: 10.6084/m9.figshare.14553783
title: Thermoresponsive copolymer nanovectors improve the bioavailability of retrograde inhibitors_LC-MS dataset.xlsx

description: LC/MS dataset for the estimation of Retro-2 Incorporation into RAW264.7 macrophages by Liquid Chromatography/Mass Spectrometry.Manuscript submitted to Frontiers in Cellular and Infection Microbiology Parasite and Host
DOI: 10.6084/m9.figshare.14553783.v1
title: Thermoresponsive copolymer nanovectors improve the bioavailability of retrograde inhibitors_LC-MS dataset.xlsx

description: LC/MS dataset for the estimation of Retro-2 Incorporation into RAW264.7 macrophages by Liquid Chromatography/Mass Spectrometry.Manuscript submitted to Frontiers in Cellular and Infection Microbiology Parasite and Host
DOI: 10.34740/kaggle/dsv/2203947
title: Dutch News Articles
DOI: 10.25345/c54n7z
title: MassIVE MSV000087379 - GNPS_Srigolactone_Hemp_exsudat-10-12_method_MS02_traite2
title: Research in hemp exudate of cannabis sativa strigolactone by MS/MS with various Strigolactone control and a blank in acetonitrile.
DOI: 10.6084/m9.figshare.14554203
title: raw data_Mallard_proteins_BTSI_morpho.txt

description: Raw data accompayining submitted manuscript on the role of partial incubation on the aterations of egg-white antimicrobial proteins (LSM and avidin) and intensity and incidence of bacterial trans-shell infection and hatchlings phenotype.
DOI: 10.6084/m9.figshare.14554203.v1
title: raw data_Mallard_proteins_BTSI_morpho.txt

description: Raw data accompayining submitted manuscript on the role of partial incubation on the aterations of egg-white antimicrobial proteins (LSM and avidin) and intensity and incidence of bacterial trans-shell infection and hatchlings phenotype.
DOI: 10.6084/m9.figshare.12721691
title: Data for 'Yachts and marinas as hotspots of coastal risk'

description: This data set accompanies the article 'Yachts and marinas as hotspots of coastal risk' (Lazarus & Ziros, 2020).<br>This repository includes data on superyacht insurance claims from the Mediterranean, filed between 1987–2017 with Pantaenius Yacht Insurance.<br><br>Table 1 is a .csv file with five columns: (1) the value of the claim filed, in 2012€; (2) the year and (3) month in which the claim was filed; (4) the country in which the damaging incident occurred; and (5) whether the damage was described in the filing as being related to a storm event.<br><br>Table 2 is a .csv file containing the locations of all storm-related claims (1987–2017). The table has two colums: (1) easting, and (2) northing. An entry of (0,0) indicates that no location was provided for that claim. For purposes of data protection, the order in which these locations appear do not correpsond to the order in which storm-related claims appear in Table 1.<br>Table 3 is a .csv file containing the locations of all non-storm-related claims (1987–2017). The table has two colums: (1) easting, and (2) northing. An entry of (0,0) indicates that no location was provided for that claim. For purposes of data protection, the order in which these locations appear do not correpsond to the order in which non-storm-related claims appear in Table 1.
DOI: 10.6084/m9.figshare.12721691.v1
title: Data for 'Yachts and marinas as hotspots of coastal risk'

description: This data set accompanies the article 'Yachts and marinas as hotspots of coastal risk' (Lazarus & Ziros, 2020).<br>This repository includes data on superyacht insurance claims from the Mediterranean, filed between 1987–2017 with Pantaenius Yacht Insurance.<br><br>Table 1 is a .csv file with five columns: (1) the value of the claim filed, in 2012€; (2) the year and (3) month in which the claim was filed; (4) the country in which the damaging incident occurred; and (5) whether the damage was described in the filing as being related to a storm event.<br><br>Table 2 is a .csv file containing the locations of all storm-related claims (1987–2017). The table has two colums: (1) easting, and (2) northing. An entry of (0,0) indicates that no location was provided for that claim. For purposes of data protection, the order in which these locations appear do not correpsond to the order in which storm-related claims appear in Table 1.<br>Table 3 is a .csv file containing the locations of all non-storm-related claims (1987–2017). The table has two colums: (1) easting, and (2) northing. An entry of (0,0) indicates that no location was provided for that claim. For purposes of data protection, the order in which these locations appear do not correpsond to the order in which non-storm-related claims appear in Table 1.
DOI: 10.6084/m9.figshare.12205307
title: Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan

description: Enzyme replacement therapy with idursulfase has been shown to improve somatic signs and symptoms of mucopolysaccharidosis type II (MPS II). Idursulfase is available in Japan (since 2007), based on the outcome of clinical trials conducted in the United States, but data from Japanese patients are limited. This was a postmarketing study of Japanese MPS II patients treated with 0.5 mg/kg intravenous idursulfase weekly, conducted over a period of 8 years after initial administration. Assessments included the safety profile, survival rate, degree of clinical improvement, change in urinary uronic acid (UA) concentration, and 6-minute walk test (6MWT). The safety and efficacy analysis populations included 145 and 143 patients, respectively. The incidence of serious adverse events was 42.8% and the incidence of adverse drug reactions was 48.3%. The 7-year survival rate was 82.7%. Improvements in the clinical features of hepatosplenomegaly, skin, joint, and respiratory disorders were reported (per investigator’s assessment). The mean change in urinary UA concentration was −128.39 mg/g creatinine, and that of 6MWT walking distance was +31.8 m. Long-term idursulfase treatment was well tolerated, and effective in improving clinical features, reducing urinary UA, and slowing disease progression in Japanese MPS II patients.
DOI: 10.6084/m9.figshare.12205307.v1
title: Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan

description: Enzyme replacement therapy with idursulfase has been shown to improve somatic signs and symptoms of mucopolysaccharidosis type II (MPS II). Idursulfase is available in Japan (since 2007), based on the outcome of clinical trials conducted in the United States, but data from Japanese patients are limited. This was a postmarketing study of Japanese MPS II patients treated with 0.5 mg/kg intravenous idursulfase weekly, conducted over a period of 8 years after initial administration. Assessments included the safety profile, survival rate, degree of clinical improvement, change in urinary uronic acid (UA) concentration, and 6-minute walk test (6MWT). The safety and efficacy analysis populations included 145 and 143 patients, respectively. The incidence of serious adverse events was 42.8% and the incidence of adverse drug reactions was 48.3%. The 7-year survival rate was 82.7%. Improvements in the clinical features of hepatosplenomegaly, skin, joint, and respiratory disorders were reported (per investigator’s assessment). The mean change in urinary UA concentration was −128.39 mg/g creatinine, and that of 6MWT walking distance was +31.8 m. Long-term idursulfase treatment was well tolerated, and effective in improving clinical features, reducing urinary UA, and slowing disease progression in Japanese MPS II patients.
DOI: 10.6084/m9.figshare.12850277
title: Stakeholders’ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases

description: Biologics are used as effective therapeutics to treat a variety of diseases. Even though biologics are widely used, knowledge on the post-marketing experience of patients is limited. Therefore, a framework was established for a patient-reported outcome measure (PROM)-based drug safety monitoring system for ADRs attributed to biologics, known as the ‘Dutch Biologic Monitor’. Generation of a multi-stakeholder perspective on the preferred setup, potential and added value of a PROM-based national drug safety monitoring system. Nineteen stakeholders were interviewed following a structured interview guide. Transcribed data were coded and analyzed to count frequencies and to generate recurring themes. Stakeholders (84.2%) support the establishment of a national drug safety monitoring system, but the feasibility depends on the implementation process. The need for integration and assessment of PROMs on ADRs in clinical practice and the preference to monitor small molecules and new drugs were emphasized. Preferably, all pharmacological options per indication should be monitored. Stakeholders recommend to establish a PROM-based national drug safety monitoring system focused on ADRs attributed to biologics, small molecules, and new drugs. Moreover, PROMs on ADRs ideally need to become integrated in clinical practice to provide health-care providers more insight in patients’ perspectives.
DOI: 10.6084/m9.figshare.12850277.v1
title: Stakeholders’ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases

description: Biologics are used as effective therapeutics to treat a variety of diseases. Even though biologics are widely used, knowledge on the post-marketing experience of patients is limited. Therefore, a framework was established for a patient-reported outcome measure (PROM)-based drug safety monitoring system for ADRs attributed to biologics, known as the ‘Dutch Biologic Monitor’. Generation of a multi-stakeholder perspective on the preferred setup, potential and added value of a PROM-based national drug safety monitoring system. Nineteen stakeholders were interviewed following a structured interview guide. Transcribed data were coded and analyzed to count frequencies and to generate recurring themes. Stakeholders (84.2%) support the establishment of a national drug safety monitoring system, but the feasibility depends on the implementation process. The need for integration and assessment of PROMs on ADRs in clinical practice and the preference to monitor small molecules and new drugs were emphasized. Preferably, all pharmacological options per indication should be monitored. Stakeholders recommend to establish a PROM-based national drug safety monitoring system focused on ADRs attributed to biologics, small molecules, and new drugs. Moreover, PROMs on ADRs ideally need to become integrated in clinical practice to provide health-care providers more insight in patients’ perspectives.
DOI: 10.6084/m9.figshare.13019467
title: Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review

description: Neurodevelopmental disorders (NDDs) are a group of complex and heterogeneous disorders, caused by the disruption of normal brain development. Antipsychotic agents are frequently used in these disorders to treat maladaptive conduct. However, a systematic evaluation of their safety/tolerability in NDDs is still lacking. Given the unique neurobiology of NDDs, antipsychotics may be expected to elicit distinctive side effects. PubMed was systematically searched for all published studies from 1980 until 2020 investigating antipsychotic use in autism spectrum disorders (ASD), intellectual disability (ID), genetic syndromes (GS), attention-deficit/hyperactivity disorder (ADHD), Tourette’s Syndrome and Tic disorders (TS). All ages and study designs were included. Antipsychotics were found to mainly cause the following side effects: metabolic disturbances; sedation; prolactin increases and sexual dysfunctions; neurological and behavioral disorders; cardiological and hematological side effects. The most studied antipsychotics were aripiprazole and risperidone. Risk of side effects varied across the different NDDs. However, evidence was strongly affected by serious methodological drawbacks and lack of studies. Notably, reports on adult patients are underrepresented, mostly for ASD and ADHD.
DOI: 10.6084/m9.figshare.13019467.v1
title: Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review

description: Neurodevelopmental disorders (NDDs) are a group of complex and heterogeneous disorders, caused by the disruption of normal brain development. Antipsychotic agents are frequently used in these disorders to treat maladaptive conduct. However, a systematic evaluation of their safety/tolerability in NDDs is still lacking. Given the unique neurobiology of NDDs, antipsychotics may be expected to elicit distinctive side effects. PubMed was systematically searched for all published studies from 1980 until 2020 investigating antipsychotic use in autism spectrum disorders (ASD), intellectual disability (ID), genetic syndromes (GS), attention-deficit/hyperactivity disorder (ADHD), Tourette’s Syndrome and Tic disorders (TS). All ages and study designs were included. Antipsychotics were found to mainly cause the following side effects: metabolic disturbances; sedation; prolactin increases and sexual dysfunctions; neurological and behavioral disorders; cardiological and hematological side effects. The most studied antipsychotics were aripiprazole and risperidone. Risk of side effects varied across the different NDDs. However, evidence was strongly affected by serious methodological drawbacks and lack of studies. Notably, reports on adult patients are underrepresented, mostly for ASD and ADHD.
DOI: 10.6084/m9.figshare.13047997
title: Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis

description: The aim of this study was to evaluate the effectiveness of interventions used for improving ADR reporting by patients and healthcare professionals. A systematic review of literature was conducted by searching Medline, Embase and Cochrane Central Register of Controlled of Trials. Meta-analysis of randomized controlled trials (RCTs; <i>n</i> = 5) was conducted to estimate the pooled risk ratio for the effectiveness of interventions on ADR reporting rates. Data from observational studies were synthesized using narrative synthesis approach. A total of 28 studies were included. All except one study targeted healthcare professionals using educational, technological, policy, financial and/or mixed interventions. The results showed that financial and face-to-face educational interventions improved quality and quantity of ADR reporting when compared with interventions not involving face-to-face interactions. However, the quality of studies was generally low. Meta-analysis showed a statistically significant 3.5-fold overall increase in reporting of ADRs [RR 3.53; 95% CI (1.77,7.06)] in the intervention group compared to the control. There was a lack of consideration of theory and sustainability in the design of the interventions. There is a need to develop and test theory-based interventions and target patient reporting. More research needs to be conducted in the low- and middle-income countries.
DOI: 10.6084/m9.figshare.13047997.v1
title: Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis

description: The aim of this study was to evaluate the effectiveness of interventions used for improving ADR reporting by patients and healthcare professionals. A systematic review of literature was conducted by searching Medline, Embase and Cochrane Central Register of Controlled of Trials. Meta-analysis of randomized controlled trials (RCTs; <i>n</i> = 5) was conducted to estimate the pooled risk ratio for the effectiveness of interventions on ADR reporting rates. Data from observational studies were synthesized using narrative synthesis approach. A total of 28 studies were included. All except one study targeted healthcare professionals using educational, technological, policy, financial and/or mixed interventions. The results showed that financial and face-to-face educational interventions improved quality and quantity of ADR reporting when compared with interventions not involving face-to-face interactions. However, the quality of studies was generally low. Meta-analysis showed a statistically significant 3.5-fold overall increase in reporting of ADRs [RR 3.53; 95% CI (1.77,7.06)] in the intervention group compared to the control. There was a lack of consideration of theory and sustainability in the design of the interventions. There is a need to develop and test theory-based interventions and target patient reporting. More research needs to be conducted in the low- and middle-income countries.
DOI: 10.6084/m9.figshare.13468950
title: Effectiveness and sustainability of deprescribing for hospitalized older patients near end of life: a systematic review

description: <b>Introduction</b>: Polypharmacy is prevalent in hospitals and deprescribing strategies for older people are strongly promoted. However, evidence of their feasibility and sustainability among patients receiving end of life care is lacking. The objective of this review was to ascertain effectiveness and post-discharge sustainability of hospital-initiated deprescribing strategies in older people near the end of life. <b>Areas covered</b>: The authors searched for controlled trials, with low risk of bias and measures of effectiveness post-discharge. Intervention description, duration, and healthcare provider engagement were investigated for their impact on reduction of number of medications, proportions of patients prescribed inappropriate medications, returns to emergency, hospital admission and adverse events. <b>Expert opinion</b>: Limited evidence suggests hospital-initiated deprescribing interventions may reduce prescribing inappropriateness among older terminal patients in the short term, but evidence beyond 3 months is lacking for significant prevention of adverse events or health service utilization. Heterogeneity precluded meta-analysis, and short follow-up periods precluded quantitative assessment of sustainability. Trials of older people with terminal conditions with larger sample sizes and longer follow-up periods are needed to confirm the effectiveness and sustainability of deprescribing at the end of life. Objective tools to reliably identify near end-of-life status would be useful in selecting target groups for these interventions.
DOI: 10.6084/m9.figshare.13468950.v1
title: Effectiveness and sustainability of deprescribing for hospitalized older patients near end of life: a systematic review

description: <b>Introduction</b>: Polypharmacy is prevalent in hospitals and deprescribing strategies for older people are strongly promoted. However, evidence of their feasibility and sustainability among patients receiving end of life care is lacking. The objective of this review was to ascertain effectiveness and post-discharge sustainability of hospital-initiated deprescribing strategies in older people near the end of life. <b>Areas covered</b>: The authors searched for controlled trials, with low risk of bias and measures of effectiveness post-discharge. Intervention description, duration, and healthcare provider engagement were investigated for their impact on reduction of number of medications, proportions of patients prescribed inappropriate medications, returns to emergency, hospital admission and adverse events. <b>Expert opinion</b>: Limited evidence suggests hospital-initiated deprescribing interventions may reduce prescribing inappropriateness among older terminal patients in the short term, but evidence beyond 3 months is lacking for significant prevention of adverse events or health service utilization. Heterogeneity precluded meta-analysis, and short follow-up periods precluded quantitative assessment of sustainability. Trials of older people with terminal conditions with larger sample sizes and longer follow-up periods are needed to confirm the effectiveness and sustainability of deprescribing at the end of life. Objective tools to reliably identify near end-of-life status would be useful in selecting target groups for these interventions.